Matilde Yáñez Jato
Dra. Matilde Yáñez Jato
Investigadora Contratada Postdoctoral
Instituto Teófilo Hernando
Facultad de Medicina
Universidad Autónoma de Madrid
C/Arzobispo Morcillo 4
28029 Madrid
e-mail: matilde.yannez@uam.es
Licenciada y doctora en Farmacia por la Universidad de Santiago de Compostela (2004). Ha trabajado en la Universidad de Santiago de Compostela desde 2002. En el año 2008 se incorpora al Instituto Teofilo Hernando de I+D del medicamento, donde en la actualidad completa sus estudios de investigación con un contrato post-doctoral del programa Angeles Alvariño de la Xunta de Galicia.
Líneas de Investigación:
-Estudio de los efectos cardiovasculares y neuroprotectores del resveratrol y de otros compuestos polifenólicos presentes en el vino tinto.
Publicaciones más relevantes
1.- SANTANA L, GONZÁLEZ-DÍAZ H, QUEZADA E, URIARTE E, YÁÑEZ M, VIÑA D and ORALLO F. “Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors”. Journal of Medical Chemistry 51:6740-6751 (2008).
2.- CHIMENTI F, MACCIONI E, SECCI D, BOLASCO A, CHIMENTI P, GRANESE A, CARRADORI S, ALCARO S, ORTUSO F, YÁÑEZ M, ORALLO F, CIRILLI R, FERRETTI R and LA TORRE F. Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones. Journal of Medical Chemistry 51:4874-4880 (2008).
3.- MEYERS C, YÁÑEZ M, ELMAATOUGI A, VERHELST T, COELHO A, FRAIZ N, LEMIÈRE GL, GARCÍA-MERA X, LAGUNA R, CANO E, MAES BU and SOTELO E. 2-Substituted 4-, 5-, and 6-[(1E)-3-oxo-3-phenylprop-1-en-1-yl]pyridazin-3(2H)-ones and 2-substituted 4,5-bis[(1E)-3-oxo-3-phenylprop-1-en-1-yl]pyridazin-3(2H)-ones as potent platelet aggregation inhibitors: design, synthesis, and SAR studies. Bioorganic Medical Chemistry Letters18:793-799 (2008).
4.- COELHO A, RAVIÑA E, FRAIZ N, YÁÑEZ M, LAGUNA R, CANO E and SOTELO E. Design, synthesis, and structure-activity relationships of a novel series of 5-alkylidenepyridazin-3(2H)-ones with a non-cAMP-based antiplatelet activity. Journal of Medical Chemistry 50:6476-6484 (2007).
5.- YÁÑEZ M, FRAIZ N, CANO E and ORALLO F. Inhibitory effects of cis- and trans-resveratrol on noradrenaline and 5-hydroxytryptamine uptake and on monoamine oxidase activity. Biochemistry and Biophysic Research Communications 344:688-695 (2006).
6.- CRESPO A, MEYERS C, COELHO A, YÁÑEZ M, FRAIZ N, SOTELO E, MAES BU, LAGUNA R, CANO E, LEMIÈRE GL and RAVIÑA E. Pyridazines part 41: synthesis, antiplatelet activity and SAR of 2,4,6-substituted 5-(3-oxo-3-phenylprop-1-en-1-yl)- or 5-(3-phenylprop-2-enoyl)pyridazin-3(2H)-ones. Bioorganic Medical Chemistry Letters 16:1080-1083 (2006).
7.- VILAR S, QUEZADA E, SANTANA L, URIARTE E, YÁÑEZ M, FRAIZ N, ALCAIDE C, CANO E and ORALLO F. Design, synthesis, and vasorelaxant and platelet antiaggregatory activities of coumarin-resveratrol hybrids Bioorganic Medical Chemistry Letters 16:257-261 (2006).
8.- YÁÑEZ M, FRAIZ N, CANO E and ORALLO F. (-)-Trans-epsilon-viniferin, a polyphenol present in wines, is an inhibitor of noradrenaline and 5-hydroxytryptamine uptake and of monoamine oxidase activity. European Journal of Pharmacology 542:54-60 (2006).
9.- COELHO A, SOTELO E, FRAIZ N, YÁÑEZ M, LAGUNA R, CANO E and RAVIÑA E. Pyridazines. Part 36: Synthesis and antiplatelet activity of 5-substituted-6-phenyl-3(2H)-pyridazinones. Bioorganic Medical Chemistry Letters 14:321-324 (2004).
10.- SOTELO E, FRAIZ N, YÁÑEZ M, TERRADES V, LAGUNA R, CANO E and RAVIÑA E.Pyridazines. Part XXIX: synthesis and platelet aggregation inhibition activity of 5-substituted-6-phenyl-3(2H)-pyridazinones. Novel aspects of their biological actions. Bioorganic Medical Chemistry Letters 10:2873-2882 (2002).
Deja que con tu colaboración, cada cual llegue a donde sea capaz